Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-474 in diffuse cutaneous systemic sclerosis
NL-OMON61309Phase 2Not yet recruiting
- Sponsor
- Mediar Therapeutics
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of MTX-474 in diffuse cutaneous systemic sclerosis (dcSSc), sponsored by Mediar Therapeutics. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
MTX-474
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NL-OMON61309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61309.